F-1: Mainz Biomed Eyes $8 Million Capital Raise Through Share and Warrant Offering

Mainz Biomed N.V. announces a best-efforts offering of ordinary shares and pre-funded warrants to raise capital for clinical studies, product development, and debt repayment.

Summary

• Mainz Biomed N.V. is planning to raise capital through a best-efforts offering of up to 30,769,231 ordinary shares and pre-funded warrants.
• The assumed offering price is $0.26 per ordinary share, based on the closing price on October 30, 2024.
• Pre-funded warrants are offered as an alternative for purchasers whose beneficial ownership would exceed 4.99% (or up to 9.99% with election).
• The purchase price of each pre-funded warrant will be equal to the price per ordinary share, minus $0.0001, and the remaining exercise price of each pre-funded warrant will equal $0.0001 per ordinary share.
• The company estimates net proceeds of approximately $7.135 million after deducting placement agent fees and offering expenses of approximately $865,000.
• The funds are earmarked for the eAArly Detect 2 study, development of the next-generation screening product, commercial expansion of ColoAlert, repayment of convertible debt, and general corporate purposes.
• The offering is expected to conclude one trading day after entering a securities purchase agreement.
• Maxim Group LLC is acting as the placement agent for the offering.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced disclosure requirements.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is raising capital for growth initiatives, it also faces risks related to market volatility, dilution, and compliance with Nasdaq listing requirements.

Positives

• The offering will provide capital to advance the eAArly Detect 2 study, which is designed to validate the clinical performance of the next-generation mRNA-based CRC screening test.
• The offering will provide capital to support the development of the next-generation screening product.
• The offering will provide capital to support the commercial expansion of the ColoAlert product.
• The company has the option to use the funds to repay convertible debt.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced disclosure requirements.

Negatives

• The offering is on a best-efforts basis, so there is no guarantee that the company will raise the full amount of capital it seeks.
• The market price of the company's ordinary shares may be volatile.
• Investors will experience immediate and substantial dilution as a result of this offering.
• The company does not intend to pay dividends, so investors will only be able to make a gain on their investment if the price of the ordinary shares appreciates.
• The company has been notified by Nasdaq that it is not in compliance with certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the company's ordinary shares may be volatile.
• Investors will experience immediate and substantial dilution as a result of this offering.
• The company does not intend to pay dividends.
• FINRA sales practice requirements may limit your ability to buy and sell our ordinary shares, which could depress the price of our shares.
• Volatility in our ordinary shares price may subject us to securities litigation.
• The company has been notified by Nasdaq that it is not in compliance with certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange.
• The company intends to enact a reverse stock split, and the public market may react negatively to such reverse stock split.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There is no public market for the pre-funded warrants being offered in this offering.
• Holders of the pre-funded warrants purchased in this offering will have no rights as ordinary shareholders until such holders exercise their pre-funded warrants and acquire our ordinary shares, except as otherwise provided in the pre-funded warrants.

Future Outlook

The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of convertible debt and for general corporate purposes.

Industry Context

The document highlights the growing market for colorectal cancer diagnostics, which is anticipated to surpass $30 billion by 2032. The company is positioning itself to capitalize on this trend with its ColoAlert product and next-generation mRNA-based screening test.

Comparison to Industry Standards

• The document compares the CRC and AA sensitivity and specificity results of test of our ColoAlert product as compared to some competing products.
• The document lists sensitivity and specificity results for Exact Sciences Cologuard, Freenome, Guardant Health Shield, and ColoAlert.

Legal Proceedings

• Mainz filed a lawsuit against an investment bank in 2024 in the New York State Supreme Court in New York County, asking the court to determine our and the investment banks rights and obligations under the relevant contracts by and between us and the investment bank.
• The investment bank initiated arbitration proceedings against us with the Financial Industry Regulatory Authority (FINRA).
• The arbitration panel agreed with us and on September 13, 2024, issued an order formally staying the arbitration proceeding.

Related Party Transactions

• Convertible debt related party $32,140
• Silent partnership related party 267,206

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to execute its business plan will be enhanced by the capital raised.
• Employees may be affected by the company's cost reduction measures, including personnel reductions.
• Customers may benefit from the development and commercialization of new diagnostic products.

Next Steps

• Complete the offering of ordinary shares and pre-funded warrants.
• Utilize the net proceeds for the eAArly Detect 2 study, development of the next-generation screening product, commercial expansion of ColoAlert, repayment of convertible debt, and general corporate purposes.
• Regain compliance with Nasdaq's minimum bid price requirement, potentially through a reverse stock split.
• Conduct the eAArly Detect 2 clinical study in the U.S. in 2025.

Key Dates

Keywords

capital raise, ordinary shares, pre-funded warrants, colorectal cancer, diagnostics, Mainz Biomed, offering, MYNZ